Total submissions: 1
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Women's Health and Genetics/Laboratory Corporation of America, |
RCV001078143 | SCV001167104 | pathogenic | beta Thalassemia | 2023-04-06 | criteria provided, single submitter | clinical testing | Variant summary: HBB c.[316-12T>C;316-7C>A] is a complex allele that alters two weakly conserved nucleotides located within intron 2 of the HBB gene. It has also been annotated as c.316-12_316-7delTTCCTCinsCTCCTA in the HGMD database (CX136346). The individual variants are also known under legacy nomenclature as IVS-II-839 (T>C) and IVS-II-844 (C>A) respectively. 5/5 computational tools predict no significant impact on normal splicing for each of the individual variants. However, these predictions have yet to be confirmed by functional studies. Based on the frequency of each constituent variant in the gnomAD database, this variant allele is expected to occur at a frequency of 4e-06 in 251142 control chromosomes. c.[316-12T>C;316-7C>A] has been reported in the literature in multiple individuals affected with mild Beta-plus Thalassemia (example, Waye_2013, Belisario_2015). These data indicate that the variant is very likely to be associated with disease. These variants are thought to affect the consensus splice site and interfere with processing of the primary mRNA transcript by modification of the conserved polypyrimidine tract of the splice acceptor site and causing a reduction of beta globin chain expression to around 60% of normal (Waye_2013). No clinical diagnostic laboratories have submitted clinical-significance assessments for this complex variant to ClinVar after 2014 although a submission of each of the individual component has been observed [ClinVar ID 810861, c.316-12T>C, Likely pathogenic (n=1) and Likely benign (n=1); ClinVar ID 551906, c.316-7C>A, Likely pathogenic (n=2)/Pathogenic (n=2), VUS (n=1)]. Most of the submitters reports the identification of both these variants in cis citing overlapping evidence utilized in the context of our evaluation. Based on the evidence outlined above, this complex variant was classified as Pathogenic for mild beta-plus Thalassemia. |